Drug

Brodalumab

Approved medicine

ClassInterleukin-17 receptor A antagonistResearchOngoing clinical research

Also known as Siliq.

RxNorm1872251 ChEMBLCHEMBL1742996 ATCL04AC12UNII6ZA31Y954Z

Active clinical trials

Interleukin-17 receptor A

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study

Clinical trial2026-05-13Results expected Q2 2027 · ClinicalTrials.gov

Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Clinical trial2026-01-05Completed · ClinicalTrials.gov

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis

Clinical trial2025-09-16Results expected Q4 2028 · ClinicalTrials.gov

A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Clinical trial2025-03-13Results posted · ClinicalTrials.gov

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study

Clinical trial2025-01-31Completed · ClinicalTrials.gov

A Phase 3, Randomised, Double-blind, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Brodalumab Treatment Compared to Placebo and Ustekinumab in Adolescent Subjects With Moderate-to-severe Plaque Psoriasis

Clinical trial2023-05-05Terminated · ClinicalTrials.gov

Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to Ustekinumab

Clinical trial2022-12-07Terminated · ClinicalTrials.gov

A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa Patients

Clinical trial2022-07-25Completed · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Clinical trial2021-12-21Results posted · ClinicalTrials.gov

Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar Psoriasis

Clinical trial2021-11-30Primary completion · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis

Clinical trial2021-11-26Results posted · ClinicalTrials.gov

Approval: Kyntheum (EMA)

Regulatory2017-07-17EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Brodalumab

Aliases & brands

Siliq

RxNorm CUI

1872251

ChEMBL ID

CHEMBL1742996

ATC codes

L04AC12

UNII

6ZA31Y954Z

Primary mechanism

Interleukin-17 receptor A antagonist

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Interleukin-17 receptor A

IL17RA · Q96F46

ANTAGONISTInterleukin-17 receptor A antagonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2017-07-17

Latest approval

2017-07-17

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2017-07-17Approval

Approval: Kyntheum (EMA)

Indication: Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

29 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 29

Early Phase 13Phase 13Phase 1 / 21Phase 26Phase 38Phase 48

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis

Active, not recruitingPH IVBausch Health Americas, Inc.n=22029

Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

CompletedPH IVLEO Pharman=3852026

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study

CompletedPH IVRadboud University Medical Centern=2442025

Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to Ustekinumab

TerminatedPH IVLEO Pharman=1132022

Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar Psoriasis

Unknown statusPH IVFirst OC Dermatologyn=102022

Recent completions

Trials that read out recently, adding to the completed evidence base.

Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

CompletedPH IVLEO Pharman=3852026

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study

CompletedPH IVRadboud University Medical Centern=2442025

A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa Patients

CompletedPH IRockefeller Universityn=42022

A Pilot Study of Safety and Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

CompletedPH IRockefeller Universityn=102020

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Axial Spondyloarthritis

CompletedPH IIIKyowa Kirin Co., Ltd.n=1592019

A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

CompletedPH IVLEO Pharman=2102019

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.